Scientists discover rare genetic form of neonatal diabetes

An international team of researchers has identified a previously unknown type of diabetes in newborns caused by mutations in the TMEM167A gene. This rare condition leads to both high blood sugar and neurological issues like epilepsy and microcephaly. The findings, published in a leading medical journal, could enhance understanding of insulin production in broader diabetes research.

Researchers from the University of Exeter Medical School and Université Libre de Bruxelles, along with global partners, used advanced DNA sequencing and stem cell models to uncover this hidden diabetes variant. The study focused on six infants who developed diabetes within their first six months of life, a period when over 85 percent of such cases stem from genetic changes. These children also exhibited neurological symptoms, including epilepsy and microcephaly, all linked to recessive mutations in the TMEM167A gene.

To investigate the gene's role, scientists at ULB converted stem cells into pancreatic beta cells—the insulin producers—and employed CRISPR gene-editing to mimic the mutations. The experiments revealed that damaged TMEM167A impairs cell function under stress, triggering responses that cause cell death and disrupt insulin secretion.

Dr. Elisa de Franco from the University of Exeter highlighted the breakthrough: "Finding the DNA changes that cause diabetes in babies gives us a unique way to find the genes that play key roles in making and secreting insulin. In this collaborative study, the finding of specific DNA changes causing this rare type of diabetes in 6 children, led us to clarifying the function of a little-known gene, TMEM167A, showing how it plays a key role in insulin secretion."

Professor Miriam Cnop added: "The ability to generate insulin-producing cells from stem cells has enabled us to study what is dysfunctional in the beta cells of patients with rare forms as well as other types of diabetes. This is an extraordinary model for studying disease mechanisms and testing treatments."

The TMEM167A gene proves essential for beta cells and neurons but less so for other tissues, offering insights into insulin biology. While rare, the discovery may guide research into common diabetes, which impacts nearly 589 million people globally. The work, funded by organizations including Diabetes UK and the Novo Nordisk Foundation, appears in The Journal of Clinical Investigation under the title 'Recessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome.'

Articoli correlati

Scientists in a lab boosting MeCP2 protein levels to treat Rett syndrome, showing restored neurons and mouse models.
Immagine generata dall'IA

Scientists raise MeCP2 levels by shifting MECP2 splicing in early Rett syndrome studies

Riportato dall'IA Immagine generata dall'IA Verificato

Researchers at Texas Children’s Hospital’s Duncan Neurological Research Institute and Baylor College of Medicine report an experimental gene-targeting approach designed to increase levels of the MeCP2 protein disrupted in Rett syndrome. In mouse experiments and neurons derived from patient cells, the strategy boosted MeCP2 and partially restored cellular structure, electrical activity and gene-expression patterns, according to findings published in Science Translational Medicine.

A new genetic study has identified 331 genes essential for transforming stem cells into brain cells, including a novel gene linked to neurodevelopmental disorders. Led by scientists at the Hebrew University of Jerusalem, the research highlights how early genetic disruptions can lead to conditions like autism and developmental delay. The findings, published in Nature Neuroscience, also reveal patterns in how these disorders are inherited.

Riportato dall'IA

A team led by Leonardo Ferreira at the Medical University of South Carolina is developing a novel therapy combining lab-made insulin-producing cells with engineered immune cells to protect them. Funded by $1 million from Breakthrough T1D, the approach aims to restore beta cell function without immunosuppressive drugs. This strategy builds on prior research and targets all stages of the disease.

Researchers at Texas A&M University have developed a chemogenetic system that uses caffeine to activate CRISPR gene editing in cells, potentially aiding treatments for cancer and diabetes. The method allows precise control over gene modifications by consuming small amounts of caffeine from everyday sources like coffee or chocolate. This approach aims to enhance immune responses and insulin production with reversible activation.

Riportato dall'IA Verificato

University of Michigan researchers using fruit flies report that changes in sugar metabolism can influence whether injured neurons and their axons deteriorate or persist. The work, published in *Molecular Metabolism*, describes a context-dependent response involving the proteins DLK and SARM1 that can briefly slow axon degeneration after injury, a finding the team says could inform future strategies for neurodegenerative disease research.

Researchers at UNSW Sydney have identified around 150 functional DNA enhancers in human astrocytes that regulate genes associated with Alzheimer's disease. By testing nearly 1,000 potential switches using advanced genetic tools, the team revealed how non-coding DNA influences brain cell activity. The findings, published on December 18 in Nature Neuroscience, could aid in developing targeted therapies and improving AI predictions of gene control.

Riportato dall'IA

Researchers at Oregon Health & Science University have pinpointed specific sites on NMDA receptors targeted by harmful antibodies in a rare autoimmune brain disorder known as "Brain on Fire." This discovery, published in Science Advances, could lead to more precise treatments and earlier detection. The condition affects about 1 in 1 million people annually, mainly young adults, causing severe symptoms like seizures and memory loss.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta